Spinal muscular atrophy (SMA) is a genetic disorder that affects the motor nerve cells in the spinal cord, leading to muscle weakness and atrophy. SMA mainly affect the muscles used for activities such as crawling, sitting, standing and walking. The primary treatment currently available for SMA is gene replacement therapy. The global SMA market is driven by increasing incidence of SMA, advancements in gene therapies, and rising funding for research.

The Global spinal muscular atrophy market is estimated to be valued at US$ 2089.13 Bn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the spinal muscular atrophy market are Samsung Electronics, Daktronics, Exceptional 3D, LG Electronics, Panasonic Corporation, Sony Corporation, Leyard Optoelectronic Co., Ltd., Scala, E Ink Holdings Inc., Deepsky Corporation Ltd., Intel Corporation, and Microsoft Corporation. These players are focusing on developing innovative gene therapies to treat different types of SMA.

The major opportunities in the SMA Market Growth are promising gene therapy treatments in the pipeline. Companies are conducting clinical trials of gene replacement therapies like Zolgensma and Evrysdi which have the potential to treat different forms of SMA. Advancements in gene therapy and availability of new treatment options will drive the SMA market growth.

The key players are also expanding their operations globally to capitalize on high growth opportunities in international markets. Companies are receiving approvals and launching their gene therapies in new markets like Europe and Asia Pacific which will support the global expansion of the SMA market over the forecast period.

Market drivers: Increasing research funding for SMA by governments and healthcare organizations is driving the market growth. Growing public-private partnerships for developing orphan drugs is also fueling the SMA therapeutics development.

Market restrain: High treatment cost associated with SMA gene therapies is a major challenge for market growth. Continued pricing pressure on pharmaceutical companies can restrict the SMA market potential over the coming years.


Get More Insights On Spinal Muscular Atrophy Market